Single-use once again growth engine for Sartorius

By Staff Reporter

- Last updated on GMT

Image: iStock/Melpomenem
Image: iStock/Melpomenem

Related tags Bioprocess solutions division Marketing

Sartorius reported a 22% year-on-year growth in sales in its bioprocessing division, driven by continued demand for single-use systems.

For the full year 2016, the Sartorius Group has reported total sales of €1.3bn ($1.4bn), with the company’s Bioprocess Solutions Division – described by the firm as “the growth engine in the reporting year yet again”​ – contributing €975m.

The division incorporates the firm’s portfolio of disposable upstream and downstream biomanufacturing equipment and consumables, and the 22.1% growth on 2015’s results refelects industry’s continued demand for single-use technologies.

“Our Bioprocess Solutions Division is continuing to expand strongly,”​ said CEO Joachim Kreuzburg.

“As a supplier for the biopharmaceutical industry, the division addresses a very dynamic market and is additionally gaining market share in the important North American market.”

While it was thought Europe had initially led the way in embracing single-use technologies, Sartorius reported in January 2015​ that the US had caught up. Since then the firm has continued to report double-digit quarterly growth in the business unit.

According to the firm, 2016 sales were split geographically with the EMEA representing 44% of the firm’s revenues, while the Americas made up 34%, and Asia-Pacific represented 22%.

Related news

Show more

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us


View more